|
Orthologous residues
|
|
4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, electrophoretic mobility shift, mutation of modification site, phosphopeptide mapping
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
insulin
|
|
|
|
increase
|
|
|
amino acids
|
|
|
|
increase
|
|
|
insulin
|
amino acids
|
|
|
augment treatment-induced increase
|
|
|
rapamycin
|
amino acids
|
|
|
inhibit treatment-induced increase
|
|
|
rapamycin
|
|
|
|
no change compared to control
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation, phosphorylation
|
|
Effect of modification (process):
translation, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
eIF4E (human)
|
|
Disrupts
|
|
|
far-Western, pull-down assay
|
|
|
Comments:
is required for phosphorylation of S63
|